Vor Biopharma Stock (NASDAQ:VOR)
Previous Close
$2.40
52W Range
$0.13 - $3.29
50D Avg
$0.56
200D Avg
$0.86
Market Cap
$317.40M
Avg Vol (3M)
$17.18M
Beta
-0.51
Div Yield
-
VOR Company Profile
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.